Clinical and molecular epidemiology of extended-spectrum β-lactamase - Producing Escherichia coli as a cause of nosocomial infection or colonization: Implications for control

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 37-45

  Rodríguez Baño, Jesús ^a,b   Navarro, Maria D ^a   Romero, Luisa ^a   Muniain, Miguel A ^a,b   Perea, Evelio J ^a,b   Pérez Cano, Ramon ^a,b   Hernández, Jose R ^b   Pascual, Alvaro ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; NONOXYIMINO BETA LACTAM; OXYIMINO BETA LACTAM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; CASE CONTROL STUDY; CATHETERIZATION; DIABETES MELLITUS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; GENE SEQUENCE; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION RISK; ISOELECTRIC FOCUSING; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BETA-LACTAMASES; CROSS INFECTION; EPIDEMIOLOGY, MOLECULAR; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 29244436120     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498519     Document Type: Article

References (43)

1. Paterson DL, Yu VL. Extended-spectrum β-lactamases: a call for improved detection and control. Clin Infect Dis 1999; 29:1419-22.
2. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-51.
3. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834-44.
4. Bou G, Cartelle M, Tomas M, et al. Identification and broad dissemination of trie CTX-M-14 β-lactamase in different Escherichia coli strains in the northwest area of Spain. J Clin Microbiol 2002; 40:4030-6.
5. Rodríguez-Baño J, Navarro MD, Romero L, et al. Epidemiology and clinical features of extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
6. Eckert C, Gautier V, Saladin-Allard M, et al. Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother 2004; 48:1249-55.
7. Ma L, Ishii Y, Chang FY, Yamaguchi K, Ho M, Siu LK. CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum β-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother 2002; 46: 1985-8.
8. Quinteros M, Radice M, Gardella N, et al. Extended-spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother 2003; 47:2864-7.
9. CTX-M genes. Clin Infect Dis 2004; 38:1736-41.
10. Moland ES, Black JA, Hossain A, Hanson ND, Thomson KS, Pottumarthy S. Discovery of CTX-M-like extended-spectrum β-lactamases in Escherichia coli isolates from five US states. Antimicrob Agents Chemother 2003; 47:2382-3.
11. Hernández JR, Pascual A, Canton R, Martínez-Martínez L. Escherichia coli y Klebsiella pneumonias productores de β-lactamasas de espectro extendido en hospitales españoles (proyecto GEIH-BLEE 2000). Grupo de Estudio de Infección Hospitalaria (GEIH). Enferm Infecc Microbiol Clin 2003; 21:77-82.
12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16:128-40.
13. McCabe WR, Jackson GG. Gram-negative bacteremia I: etiology and ecology. Arch Intern Med 1962; 110:847-55.
14. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: fifth edition. NCCLS document M7-A5. Wayne, PA: NCCLS, 2002.
15. NCCLS. Performance standards for antimicrobial susceptibility testing, twelfth informational supplement. NCCLS document M100-S12. Wayne, PA: NCCLS, 2002.
16. Vila J, Marcos MA, Jiménez de Anta MT. A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex. J Med Microbiol 1996; 44:482-9.
17. Barret TJ, Lior H, Green JH, et al. Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing. J Clin Microbiol 1994; 32:3013-7.
18. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
19. Matthew M, Harris AM, Marshall MJ, Ross GW. The use of analytical isoelectric focusing for detection and identification of β-lactamases. J Gen Microbiol 1975; 88:169-78.
20. Bush K, Singer SB. Effective cooling allows sonication to be used for liberation of β-lactamases from gram-negative bacteria. J Antimicrob Chemother 1989; 24:82-4.
21. Jacoby J, Bush K. Amino acid sequences for TEM, SHV, and OXA extended-spectrum and inhibitor resistant β-lactamases [cited 2005 15 June]. Available at: http://www.lahey.org/studies/webt.htm. Accessed 15 June 2005.
22. Coque TM, Oliver A, Perez-Diaz JC, Baquero F, Canton R. Genes enconding TEM-4, SHV-2, and CTX-M-10 extended-spectrum β-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 2002; 46:500-10.
23. Oliver A, Perez-Diaz JC, Coque TM, Baquero F, Canton R. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing β-lactamase (CTX-M-10). Antimicrob Agents Chemother 2001; 45:616-20.
24. Rasheed JK, Jay C, Metchock B, et al. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41: 647-53.
25. Simarro E, Navarro F, Ruiz J, Miri E, Gomez J, Mirellis B. Salmonella enterica serovar Virchow with CTX-M-like β-lactamase in Spain. J Clin Microbiol 2000; 38:4676-8.
26. National Institutes of Health. Basic local alignment search tool (BLAST). Available at: http://www.ncbi.nlm.nih.gov/BLAST. Accessed 15 June 2005.
27. Infobiogen. Traduction multiple. Available at: http://www.infobiogen .fr/services/analyseq/cgi-bin. Accessed 15 June 2005.
28. D'Agata E, Venkataraman L, DeGirolami P, Weigel L, Samore M, Tenover F. The molecular and clinical epidemiology of Enterobacteriaceae-producing extended-spectrum β-lactamase in a tertiary care hospital. J Infect 1998; 36:279-85.
29. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517-23.
30. Lucet JC, Deeré D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a University Hospital. Clin Infect Dis 1999; 29:1411-8.
31. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
32. Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002;23:254-50.
33. Yagi T, Kurokawa H, Senda K, et al. Nosocomial spread of cephemresistant Escherichia coli strains carrying multiple Toho-1-like β-lactamase genes. Antimicrob Agents Chemother 1997; 41:2606-11.
34. Palucha A, Mikiewicz B, Gniadkowski M. Diversification of Escherichia coli expressing an SHV-type extended-spectrum β-lactamase (ESBL) during a hospital outbreak: emergence of an ESBL-hyperproducing strain resistant to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1999; 43:393-6.
35. Romero L, López L, Rodríguez-Baño J, Hernández JR, Martínez-Martínez L, Pascual A. Long-term study of the frequency of ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates. Clin Microbiol Infect 2005; 11:625-31.
36. Paterson DL, Singh N, Ribs JD, Squier C, Rihs BL, Muder RR. Control of outbreak of infection due to extended-spectrum β-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001; 33:126-8.
37. Mulvey MR, Bryce E, Boyd D, et al. Amber class A extended-spectrum β-lactamase-preducing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother 2004; 48:1204-14.
38. Fang H, Lundberg C, Olsson-Liljequist B, et al. Molecular epidemiologic analysis of Escherichia coli isolates producing extended-spectrum β-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden. J Clin Microbiol 2004; 42:5917-20.
39. Rodríguez-Baño J, Pascual A, Muniain MA, et al. Description of endemic multidrug-resistant Acinetobacter baumannii and efficacy of a control program [abstract 1725]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Canada). Washington, DC: American Society for Microbiology, 2000:428.
40. Harris AD, Karchmer TB, Carmeli Y, Samore SH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:1055-61.
41. McDonald LC, Jarvis WR. Linking antimicrobial use to nosocomial infections: the role of a combined laboratory-epidemiology approach. Ann Intern Med 1998; 129:245-7
42. Paterson DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis 2002; 34:1564-7.
43. Poirel L, Naas T, Le Thomas I, Karim A, Bingen E, Nordmann P. CTX-M-type extended-spectrum β-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob Agents Chemother 2001; 45:3355-61.